For WHO grade 4 gliomas, the astrocytomas with IDH1-mut benefited when resecting the non-contrast-enhancing (NCE) tumor on the basis of resecting the contrast-enhancing (CE) tumor. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).